Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients

作     者：Rui Huang Chen-Chen Yang Yong Liu Juan Xia Ran Su Ya-Li Xiong Gui-Yang Wang Zhen-Hua Sun Xiao-Min Yan Shan Lu Chao Wu 

作者机构：Department of Infectious DiseasesNanjing Drum Tower HospitalNanjing University Medical School Department of Infectious DiseasesQidong People’s Hospital Department of Laboratory MedicineNanjing Drum Tower HospitalNanjing University Medical School Department of MedicineUniversity of Massachusetts Medical School 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第34期

页      面：9957-9965页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Supported by National Natural Science Foundation of China,No.81470093 Jiangsu Provincial Outstanding Medical Academic Leader Program,No.LJ201154 Jiangsu Provincial Clinical Medicine and Technology Special Program,No.BL2012034 

主　　题：Gamma-glutamyl transferase Hepatitis B e antigen H 

摘      要：AIM:To investigate the association of serum gammaglutamyl transferase(GGT) levels with chronic hepatitis B infection and hepatitis B e antigen(HBe Ag) ***:A retrospective study was performed on clinical data collected from patients who had been positive for hepatitis B surface antigen for 6 mo and who were antiviral-treatment na?ve(n = 215) attending the Hepatitis Clinic at Nanjing Drum Tower Hospital between August 2010 and December 2013. Healthy individuals without liver disease(n = 83) were included as controls. Patients were categorized into four groups based on disease status as recommended by the European Association for the Study of the Liver:immune tolerance(IT; n = 47),HBe Ag-positive hepatitis(EPH; n = 93),HBe Ag-negative hepatitis(ENH;n = 20),and inactive carrier(IC; n = 55). Prediction of complete response(CR) based on serum GGT was also examined in EPH patients(n = 33) treated for 48 wk with nucleos(t)ide analogue(NA) therapy,including lamivudine plus adefovir combination therapy(n = 20) or entecavir monotherapy(n = 13). CR was defined as a serum hepatitis B virus DNA level 500 copies/m L and HBe Ag seroconversion by 48 wk of treatment. RESULTS:Serum GGT levels were significantly increased in EPH and ENH patients relative to the IT,IC,and healthy control groups(P 0.01 for all). However,no significant difference in serum GGT levels was found between the EPH and ENH groups. Baseline serum GGT levels were significantly higher in patients who achieved CR(7/33; 21.2%) compared to patients in the non-CR group(26/33; 78.8%; P = 0.011). In addition,the decline in serum GGT was greater in CR patients compared to non-CR patients after 24 wk and 48 wk of treatment(P = 0.012 and P = 0.008,respectively). The receiver operating characteristic curve yielded a sensitivity of 85.71% and a specificity of 61.54% at a threshold value of 0.89 times the upper limit of normal for baseline serum GGT in the prediction of CR following NA therapy. CONCLUS